1  BACKGROUND INFORMATION ON THE PROCEDURE 
1.1  Submission of the dossier 
The  applicant  Bioenvision  Limited  submitted  on  27  July  2004  an  application  for  Marketing 
Authorisation  to  the  European  Medicines  Agency  (EMEA)  through  the  centralised  procedure  for 
Evoltra, which was designated as an orphan medicinal product on 5 February 2002 and 8 May 2003.  
The legal basis for this application refers to Article 8.3(i) of Directive 2001/83/EC, as amended - 
complete and independent application. 
The  application  submitted  is  a  complete  dossier  composed  of  administrative  information,  complete 
quality  data,  non-clinical  and  clinical  data  based  on  the  applicants’  own  tests  and  studies  and/or 
bibliographic literature substituting/supporting certain test(s) or study(ies). 
Protocol Assistance: 
The applicant did not seek Protocol Assistance at the CHMP. 
Licensing status: 
The US FDA authorised clofarabine on 28 December 2004.   
The Rapporteur and Co-Rapporteur appointed by the CHMP were: 
Rapporteur: 
Eric Abadie 
Co-Rapporteur: Barbara van Zwieten-Boot 
1.2  Steps taken for the assessment of the product 
•  The application was received by the EMEA on 27 July 2004.  
•  The procedure started on 16 August 2004. 
•  The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on  26 October 
2004.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on  29 
October 2004.  
•  During  the  meeting  on  13-15  December  2004,  the  CHMP  agreed  on  the  consolidated  List  of 
Questions  to  be  sent  to  the  applicant.  The  final  consolidated  List  of  Questions  was  sent  to  the 
applicant on 15 December 2004. 
•  A study related inspection of the laboratory that performed preclinical studies requiring GLP 
Compliance in connection with the application was conducted by the Dutch competent authority 
(VWA) and the French competent authority (AFSSAPS) between 1 and 3 February 2005.  The 
studies were found to be compliant with the requirements of OECD GLP principles. 
•  AAI  Development  Services  was  inspected  between  13  and  16  June  2005  by  the  UK  competent 
authority  (MHRA)  in  connection  with  the  application  and  found  to  be  in  compliance  with  EU 
GMP. 
•  A clarification meeting on the CHMP List of Questions was held on 22 February 2005. 
•  The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on  9 August 
2005. 
•  The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List of 
Questions to all CHMP members on 20 September 2005. 
•  During  the  CHMP  meeting  on  10-13  October  2005,  the  CHMP  agreed  on  a  list  of  outstanding 
issues to be addressed in writing by the applicant. 
•  The applicant submitted responses to the CHMP list of outstanding issues on 18 January 2006. 
•  The Rapporteurs circulated an updated Joint Assessment Report on the applicant’s responses to the 
list of outstanding issues on 6 February 2006. 
•  During the meeting on 20-23 February 2006, the CHMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing  Authorisation  to  Evoltra  on  23  February  2006.  The  applicant  provided  the  letters  of 
undertaking on the follow-up measures and specific obligations to be fulfilled post-authorisation on 
22 and 23 February 2006. 
1/2  
©EMEA 2006 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
•  The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 29 May 2006. 
2/2  
@EMEA 2006 
 
 
